Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Finished Goods (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Finished Goods for 5 consecutive years, with $1.6 billion as the latest value for Q3 2025.

  • Quarterly Finished Goods rose 40.91% to $1.6 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Sep 2025, up 40.91% year-over-year, with the annual reading at $1.6 billion for FY2025, 40.91% up from the prior year.
  • Finished Goods hit $1.6 billion in Q3 2025 for Universe Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $1.6 billion in Q3 2025 to a low of $1.3 million in Q3 2022.
  • Historically, Finished Goods has averaged $551.2 million across 5 years, with a median of $2.8 million in 2023.
  • Biggest five-year swings in Finished Goods: crashed 32.14% in 2022 and later surged 40997.28% in 2024.
  • Year by year, Finished Goods stood at $2.0 million in 2021, then crashed by 32.14% to $1.3 million in 2022, then surged by 107.64% to $2.8 million in 2023, then soared by 40997.28% to $1.1 billion in 2024, then soared by 40.91% to $1.6 billion in 2025.
  • Business Quant data shows Finished Goods for UPC at $1.6 billion in Q3 2025, $1.1 billion in Q3 2024, and $2.8 million in Q3 2023.